Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors.

Authors:
Yi M; Niu M; Wu Y; Ge H; Jiao D and 6 more

Journal:
J Hematol Oncol

Publication Year: 2022

DOI:
10.1186/s13045-022-01363-8

PMCID:
PMC9548169

PMID:
36209176

Journal Information

Full Title: J Hematol Oncol

Abbreviation: J Hematol Oncol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Hematology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Evidence found in paper:

"all raw rna-seq data are publicly available in national center for biotechnology information sequence read archive under accession number prjna837188."

Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateThe animal operations in this study were evaluated and approved by the Institutional Animal Care and Use Committee of Tongji Hospital of Huazhong University of Sciences and Technology. Consent for publicationNot applicable. Competing interestsJZ, YY, and PZ were employees of Wuhan YZY Biopharma Co., Ltd. Competing interests JZ, YY, and PZ were employees of Wuhan YZY Biopharma Co., Ltd."

Evidence found in paper:

"Funding This work was supported by the National Natural Science Foundation of China (No. 81874120, No. 82073370, No.82272794, No.62131009, and No.82072597)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025